Key Highlights

  • Ping An Biomedical's fiscal 2025 Revenue fell to about RMB 34.2 million from roughly RMB 87.6 million, with Gross Profit shrinking to under RMB 1 million and the net loss widening to about RMB 12.8 million.
  • Kandal M Venture reported fiscal 2026 revenue of about $17.13 million, essentially flat year-over-year, with Net Income rising 12.4% to about $235,600 despite a 17% first-half revenue hit from U.S. tariffs.
  • Ping An Biomedical announced a planned $30 million upfront Investment in Future Biotechnology Group in January 2026, alongside a 1,000-to-1 share consolidation and a $4 million Placement priced at $0.04 per share.
  • Kandal M Venture announced a convertible note Facility of up to $25 million in June 2026 to fund a Philippine plant, with an amended F-3 registering up to about 46.2 million shares for resale on conversion.

Ping An Biomedical (NASDAQ:PASW) and Kandal M Venture (NASDAQ:FMFC) both went public on Nasdaq in mid-2025 as small, Asia-based businesses tied to the fashion Supply chain. One supplies garments and yarn to apparel customers in China; the other sews leather handbags for international brands in Cambodia. A year later their paths look very different, which shows why the operations underneath a ticker deserve more attention than the name on the door.

Ping An Biomedical (NASDAQ:PASW): An Apparel Supplier Reaching for Biotech

Ping An Biomedical listed in July 2025 as Majestic Ideal Holdings (ticker MJID) and adopted its current name a few months later. Its operating base remains apparel supply chain management through a PRC subsidiary, selling finished garments, yarns and SCM services. Its Form 20-F for the fiscal year ended September 30, 2025 flagged dependence on a few major customers, net current liabilities of about RMB 10.3 million and going-concern risk.

The numbers behind that warning are stark. According to data compiled from the company's filings, revenue for fiscal 2025 fell to about RMB 34.2 million from roughly RMB 87.6 million a year earlier, gross profit shrank to under RMB 1 million, and the net loss widened to about RMB 12.8 million. For the six months ended March 31, 2025, the company had already reported a slide into a gross loss.

Management has since pointed the company toward healthcare. In January 2026 it announced a planned investment in Future Biotechnology Group: $30 million in cash up front plus $60 million in later acquisitions paid in cash and shares. In February it disclosed a $4 million placement of 100 million shares at $0.04 each, and in March shareholders approved 100-vote Class B shares and a 1,000-to-1 share consolidation. In July 2026 it sold Hong Kong Trademark rights for $2.5 million and signed an agreement targeting RMB 500 million of health product sales over three years. Nasdaq has given it until November 23, 2026 to meet the $1 minimum bid price rule.

Kandal M Venture (NASDAQ:FMFC): A Contract Manufacturer With Thin Margins

Kandal M Venture makes affordable luxury leather goods, mainly handbags and small accessories, at its facility in Cambodia for international fashion brands. It completed its IPO in June 2025, raising net proceeds of about $8.0 million, and appointed Fok Yui Kwong as chief executive effective February 1, 2026.

In a July 30, 2026 release, Kandal reported revenue of about $17.13 million for the fiscal year ended March 31, 2026, essentially flat from $17.19 million a year earlier. Gross Margin slipped to 18.9% from 19.5% as the company added quality control staff, but net income rose 12.4% to about $235,600 on lower interest expense. Cash was about $3.58 million at year-end, up from roughly $103,000. Because U.S. tariffs had cut first-half revenue by 17%, the full-year figure implies a stronger second half.

Growth plans center on the Philippines. In March 2026 Kandal agreed to buy 15% of Dumaine International for $2.5 million, and in June it announced a convertible note facility of up to $25 million to equip a Philippine plant. An amended F-3 filed in August registered up to about 46.2 million shares for resale on conversion of those notes, against 15.3 million Class A shares outstanding, and disclosed a December 21, 2026 deadline to cure a bid price deficiency. Shareholders were also asked on July 9, 2026 to approve a 1-for-16 share consolidation.

Why Operating Substance Matters More Than the Label

Both stocks sit in the apparel supply chain on paper, but the businesses tell different stories. Kandal is a working factory: modest, profitable at the net line, with revenue that held steady through a Tariff shock. Ping An Biomedical's apparel operations shrank sharply and lost money, while its stated future rests on biotech deals not yet visible in reported revenue. The useful question is less "which sector?" than "what is actually generating the cash?"

  • Revenue quality: Is revenue recurring from real customers, or tied to agreements not yet reported as sales?
  • Margins: Kandal's roughly 19% gross margin leaves little room for cost shocks; Ping An's legacy margin was near zero in fiscal 2025.
  • Funding source: Kandal relies on convertible notes with conversion floors; Ping An has used low-priced share placements and a dual-class structure that concentrates voting power.
  • Follow-through: Do announced deals, such as the Future Biotechnology investment, close as stated?

Using the Nasdaq Composite as a Benchmark

The Nasdaq Composite tracks thousands of Nasdaq-listed stocks and is dominated by large technology names, making it a useful gauge of the market backdrop. Comparing a microcap's return and Volatility with the index over the same window helps separate company-specific moves from broad swings. The index is used here purely as a comparison benchmark, not as a claim that either company carries meaningful weight in it.

The gap can be extreme. Kandal's shares have ranged from about $0.19 to $15.75 over the past 52 weeks, and both stocks trade below $1. Consolidations, conversions and placements can change per-share figures overnight, so index comparisons should be read alongside share-count changes.

Risks

For Ping An Biomedical, the main risks are going-concern doubt, customer concentration, a declining legacy business, dilution from placements priced at a few cents, and execution risk on a biotech pivot with little reported history. The dual-class structure concentrates voting control, and internal control weaknesses have been disclosed.

Kandal's risks are more operational. It depends on a few Brand customers and on U.S. trade policy, and margins are thin. The convertible notes could greatly enlarge the share count, and it must regain bid price compliance by late December 2026 or face possible delisting. The Philippine expansion adds cost before any benefit appears.

Revenue, Margins and Share Count Clarify What Each Stock Represents

Ping An Biomedical and Kandal M Venture show how two small apparel-linked listings can diverge within a year. Kandal remains a modestly profitable leather goods manufacturer funding growth with dilutive debt, while Ping An Biomedical is trying to reinvent a shrinking, loss-making supply chain Business as a biomedical company. Looking past the sector label to revenue, margins, cash and share count clarifies what each stock represents.